Additional Analyses Show Custirsen Lowered Serum Clusterin Levels in CRPC Patients

GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis

If you listen to GRAIL executives discuss the results of the long-awaited trial of the company’s multicancer detection test, you might be led to conclude that the company’s pivotal NHS-Galleri study had an overwhelmingly positive result.

March 06, 2026

By Jacquelyn Cobb and Sara Willa Ernst

Conversation with The Cancer Letter

GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ

Undeterred by the negative topline result of its pivotal trial of Galleri, a multicancer detection test, the test’s sponsor, GRAIL, said it’s forging ahead with its plan to get FDA approval and reimbursement from CMS and private insurers.

March 06, 2026

By Jacquelyn Cobb and Sara Willa Ernst

Conversation with The Cancer Letter

NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs

Philip E. Castle, director of the NCI Division of Cancer Prevention, said he was disappointed to hear that GRAIL’s NHS-Galleri trial did not meet its primary endpoint of reduction in late-stage cancers.

March 06, 2026

By Jacquelyn Cobb and Sara Willa Ernst

Obituary

Erin Cummings, Cancer Nation advocate, dies of stomach cancer at 68

Erin Geddis Cummings , advocate and founder of Hodgkin’s International, died on Feb. 24, at Martha’s Vineyard Hospital, surrounded by her family. She was 68.

March 06, 2026

Vasan Yegnasubramanian: How AI is transforming cancer research and treatment

Vasan Yegnasubramanian, MD, PhD, is the director of Precision inHealth Medicine at Johns Hopkins. He spoke with Johns Hopkins Kimmel Cancer Center communications staff about how AI is transforming cancer research and treatment. The transcript of the conversation follows.

March 06, 2026

By John’s Hopkins Kimmel Cancer Center Communications

Cancer Policy

Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members

Mount Sinai hospital has formed a committee to investigate the ties between Jeffrey Epstein and Eva Dubin a leading doctor at the hospital and founder of the Dubin Breast Center at the Tisch Cancer Institute whose name is featured prominently in the Epstein files.

March 06, 2026

By Claire Marie Porter and Sara Willa Ernst

Additional Analyses Show Custirsen Lowered Serum Clusterin Levels in CRPC Patients

YOU MAY BE INTERESTED IN

GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis

GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ

NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs

Erin Cummings, Cancer Nation advocate, dies of stomach cancer at 68

Vasan Yegnasubramanian: How AI is transforming cancer research and treatment

Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members

Renew today!

Subscriber content

Never miss an issue!

Login

Additional Analyses Show Custirsen Lowered Serum Clusterin Levels in CRPC Patients

YOU MAY BE INTERESTED IN

GRAIL presses on with Galleri test despite missed primary endpoint in pivotal studyWhere GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis

GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”Mainstream epidemiologists beg to differ

NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs

Erin Cummings, Cancer Nation advocate, dies of stomach cancer at 68

Vasan Yegnasubramanian: How AI is transforming cancer research and treatment

Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members

Never miss an issue!

Login

GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis

GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ

NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs